Prime Medicine considers focus on autoimmune diseases for CAR-T, CEO says

Prime Med­i­cine is con­sid­er­ing de­vel­op­ing cell ther­a­pies for au­toim­mune dis­eases and will like­ly look for a part­ner for can­cer cell ther­a­pies, CEO Kei­th Gottes­di­ener said dur­ing a talk at the Gold­man Sachs Glob­al Health­care Con­fer­ence on Mon­day.

By do­ing so, the biotech would join a grow­ing list of aca­d­e­m­ic groups and com­pa­nies cre­at­ing CAR-T ther­a­pies for au­toim­mune con­di­tions like lu­pus. CAR-T ther­a­pies were first de­vel­oped for can­cer and have been trans­for­ma­tive for pa­tients who are able to ac­cess them.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN